1.The effect of bile reflux on the intragastric pH
Jun GONG ; Ru ZHANG ; Jinyan LUO
Journal of Pharmaceutical Analysis 2001;13(1):29-
Oblective To observe the effect of bile reflux on the intragastric pH. Methods We used ambulatory intragastric pH monitoring along with simultaneous Bilitec 2000 to measure the pH and absorbance of the mixed gastric juice diluted with bile with increasing bilirubin concentration in vitro and the yellow and clear gastric juice aspirated under endoscopy. In vivo,we studied 20 functional dispepsia patients for 24 h with simultaneous intragastric pH and bilirubin monitoring. Results In vitro dilutions,the absorbance value reached to 0. 900 while the concentration was only 20% ,but when the pH of the solution was more than 4,it′s concentration was already up to 60%. The mean absorbance of the yellow gastric juice(0. 348± 0. 131) was significantly higher than that of the clear juice (0. 008 ± 0. 003)(P<0.05). The pH of 80% yellow gastric juice was less than 4, the percentage was not significantly different from the clear samples (81%) (P>0. 05). The pH showed no correlation with the absorbance in the yellow and clear groungs. Eight of the 12 patients with the spontaneous nocturnal episcodes of alkalinization had simultaneous increase of absorbance,4 of the 8 subjects with no aikalinization had increase of absorbance. Gonclusion In some concentration,bile reflux affect little on the intragastric pH.
2.Therapeutic effect of children's growth patch combined with recombinant human growth hormone in treatment of idiopathic short stature
Lingzhi ZHU ; Jinyan RU ; Huijun YU ; Jianmin YE ; Xiufang CHEN ; Haiying FENG
China Modern Doctor 2019;57(10):59-61,65
Objective To investigate the therapeutic effect of children's growth patch combined with recombinant human growth hormone on idiopathic short stature. Methods A retrospective analysis of 45 children patients with idiopathic short stature from February 2016 to February 2017 was carried out, according to the treatment method, they were divided into the control group, the observation group 1 and the observation group 2, with 15 cases in each group. The control group was those who rejected all medications. The observation group 1 was those who were given children's growth patch; the observation group 2 was those who were given growth patch combined with recombinant human growth hormone therapy. The treatment lasted for 12 months. The height growth, genetic height, and predicted adult height were compared. Results The control group, the observation group 1 and the observation group 2 were compared, and the height growth values were (3.87±1.25) cm, (7.93±1.53) cm, and (10.20±1.97) cm, respectively, and the difference was significant (F=59.48, P<0.01); the genetic heights were (156.80±4.94) cm, (156.07±3.97) cm, (156.13±4.58) cm, respectively, and the difference was not significant (F=0.12, P>0.05); the predicted adult heights were (155.73±3.31) cm, (164.80±5.24) cm, and (167.87±5.68) cm, respectively, and the difference was significant (F=25.35, P<0.01). Conclusion Children's growth patch combined with recombinant human growth hormone in the treatment of idiopathic short stature can significantly increase the height growth value and increase the predicted value of adult height.